Latest Breaking News On - Esperion therapeutics inc - Page 3 : vimarsana.com

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with.

San diegoUnited statesEli lillyCarmine stengoneTroy ignelziRapport therapeutics incCincor pharma incAudit committeeBristol myers squibbInsys therapeutics incKaruna therapeutics incFerris state universityEsperion therapeutics incContineum therapeutics incContineum therapeuticsChief executive officer

Esperion Therapeutics (NASDAQ:ESPR) Lowered to Buy at StockNews com

StockNews.com lowered shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Friday. A number of other equities analysts have also weighed in on the company. HC Wainwright reiterated a buy rating and set a $16.00 target price on shares of […]

Raymond james associatesConnor clark lunn investment management ltdCapital partnersEsperion therapeutics incAcadian asset managementNeedham companyEsperion therapeutics company profileEsperion therapeuticsFree reportModerate buyTherapeutics trading downGet free reportAsset managementLunn investment managementRaymond jamesEsperion therapeutics daily

Esperion Therapeutics (ESPR) Buy Rating Reiterated at HC Wainwright

Esperion Therapeutics (ESPR) Buy Rating Reiterated at HC Wainwright
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Esperion therapeutics company profileVanguard group incEsperion therapeutics incArmistice capitalCapital partnersNeedham companyEsperion therapeuticsFree reportEsperion therapeuticModerate buyGet free reportAsset managementWasatch advisorsEsperion therapeutics daily

Esperion Therapeutics (NASDAQ:ESPR) Raised to Strong-Buy at StockNews com

Esperion Therapeutics (NASDAQ:ESPR) Raised to Strong-Buy at StockNews com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Capital partnersNeedham companyEsperion therapeutics incVanguard group incArmistice capitalEsperion therapeuticsFree reportModerate buyGet free reportAsset managementEsperion therapeutics daily

Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews com to Strong-Buy

Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews com to Strong-Buy
modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.

Portfolio partnersSimplicity wealthNeedham companyEsperion therapeutics incHerbst groupEsperion therapeuticsGet free reportEsperion therapeutics daily